The HINT3 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, designed for targeted disruption of the HINT3 gene. This polyclonal pool comprises a heterogeneous mix of cells carrying diverse loss-of-function mutations introduced by non-homologous end joining, offering a robust model to interrogate HINT3 function without the bottlenecks of clonal selection. The population format preserves natural cell-to-cell variability while ensuring constitutive ablation of the target gene across the culture, making it ideal for pooled functional genomics screens, dose?Cresponse studies, and experiments requiring a representative knockout background. Researchers can use these cells to dissect HINT3-dependent processes in a setting that mirrors the complexity of heterogeneous tumor populations.
HeLa cells are an immortalized line originating from a human cervical adenocarcinoma and serve as a cornerstone model in cancer biology, signal transduction, and apoptosis research. These epithelial cells harbor integrated human papillomavirus 18 sequences, which dysregulate p53 and retinoblastoma tumor suppressors, creating a unique pro-survival context that underscores the need for precise apoptotic dissection. HeLa cells retain a competent mitochondrial apoptotic machinery, including functional BCL2 family proteins, cytochrome c release ability, and apoptosome formation, yet exhibit altered thresholds for death stimuli. This well-characterized genetic background, combined with extensive reference data on transcriptomics, proteomics, and pharmacological sensitivities, makes HeLa an informative host for investigating mitochondrial regulatory factors like HINT3.
HINT3 encodes a mitochondrial adenosine monophosphoramidase whose activity modulates nucleotide-dependent steps in the intrinsic apoptosis pathway. Under conditions of oxidative stress or genotoxic damage, HINT3 is transcriptionally regulated by tumor protein p53, positioning it as a downstream effector of p53-mediated apoptosis. The enzyme functions upstream of pro-apoptotic factor activation and caspase cascades, interacting with mitochondrial permeability transition pore components and the BAX protein. In the canonical intrinsic apoptosis network, BAX promotes cytochrome c release, which then engages APAF1 and caspase-9 to form the apoptosome. HINT3??s phosphoramidase activity may influence the local nucleotide milieu that gates these BAX-dependent events, providing a mechanistic link between mitochondrial nucleotide metabolism and apoptotic commitment.
In the HeLa cell context, HINT3 knockout provides a unique gain-of-function model to examine how loss of mitochondrial adenosine monophosphoramidase perturbs intrinsic apoptosis signaling. HeLa cells, with their dampened p53 axis and elevated anti-apoptotic BCL2 expression, often resist cytochrome c release and caspase activation. Disruption of HINT3 may shift this equilibrium by altering the sensitivity of permeability transition pore opening or BAX insertion into the outer mitochondrial membrane. Consequently, these polyclonal knockout cells allow direct investigation of whether HINT3 is required for efficient apoptosome assembly and whether its phosphoramidase activity is needed for full caspase-9 processing. The model also supports studies on metabolic reprogramming and mitochondrial stress responses linked to nucleotide pool imbalances.
Typical research applications of HINT3 Knockout HeLa Polyclonal Cells include detailed apoptosis profiling, mitochondrial function assessment, and high-throughput drug screening for apoptosis modulators. Users can employ western blotting to monitor cleavage of caspase-9 and caspase-3, cytochrome c release assays to quantify mitochondrial outer membrane permeabilization, and flow cytometry with annexin V staining to measure phosphatidylserine exposure. Mitochondrial membrane potential can be evaluated with JC-1 or TMRM dyes, while RT?qPCR assays can track expression changes in BAX, BCL2, and caspase-9 transcripts. These cells are also suited for combinatorial studies with chemotherapeutics or novel small molecules aimed at restoring apoptotic sensitivity in cervical adenocarcinoma models. For further information or to discuss custom options, please contact Ascent Research.
